Clinical significance of risedronate for patients with prostate cancer receiving androgen deprivation therapy

Japanese Journal of Urology

Volumn 99, Issue 1, 2008, Pages 22-28

  Kimura, Masaki ^a   Satoh, Takefumi ^a   Okazaki, Miyoko ^b   Tabata, Ken Ichi ^a   Tsuboi, Toshiki ^a   Hyodo, Toru ^c   Yokoyama, Eiji ^d   Matsumoto, Kazumasa ^a   Soh, Shigehiro ^a   Iwamura, Masatsugu ^a   Hayakawa, Kazushige ^a   Baba, Shiro ^a  

^a KITASATO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY HOSPITAL   (Japan)

^c Yokohama Daiichi Hospital   (Japan)

^d Yokoyama Clinic

Author keywords

Androgen deprivation therapy; Bisphosphonate; Prostate cancer

Indexed keywords

EID: 39449108836     PISSN: 00215287     EISSN: None     Source Type: Journal    
DOI: 10.5980/jpnjurol1989.99.22     Document Type: Article

References (20)

1. Akaza H. : Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer : Japanese perspective. Cancer Sei., 97, 243-7, 2006.
2. Preston DM. Torrens JI, Harding P. : Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. Prostate Cancer Prostatic Dis., 5, 304-10, 2002.
3. Greenspan SL, Coates P, Sereika SM. : Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab., 90, 6410-7, 2005.
4. Morote J. Morin JP. Orsola A. : Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology., 69, 500-4, 2007.
5. Morote J. Orsola A, Abascal JM. : Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol., 175, 1679-83, 2006.
6. Shahinian VB, Kuo YF, Freeman JL. : Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med., 352, 154-64, 2005.
7. Oefelein MG, Ricchiuti V, Conrad W. : Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol., 168, 1005-7, 2002.
8. Greene FL, Page DL, Fleming ID. : AJCC cancer staging manual, 6 th ed. New York : SpringerVerlag, 2002.
9. Mottet N. Prayer-Galetti T, Hammerer P. : Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int., 98, 20-7, 2006.
10. Harris ST, Watts NB, Genant HK. : Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis : a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA., 282, 1344-52, 1999.
11. Reginster J, Minne HW, Sorensen OH. : Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int., 11, 83-91, 2000.
12. Eastell R, Barton I, Hannon RA. : Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Minor Res., 18, 1051-56, 2003.
13. Greenspan SL, Rosen HN, Parker RA. : Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab., 85, 3537-40, 2000.
14. Groot MT, Boeken Kruger CG. : Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol., 43, 226-32, 2003.
15. Harris ST. Watts NB, Li Z. : Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin., 20, 757-64, 2004.
16. Kishimoto H, Fukunaga M, Kushida K. : Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis : a comparison with 2.5-mg once-daily dosage regimen., Bone Miner Metab., 24, 405-13, 2006.
17. Cramer JA, Amonkar MM, Hebborn A. : Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin., 21, 1453 -60, 2005.
18. Bae DC. Stein BS. : The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate. J Urol., 172, 2137-44, 2004.
19. Coxon JP, Oades GM, Colston KW. : Advances in the use of bisphosphonates in the prostate cancer setting. Prostate Cancer Prostatic Dis., 7, 99-104, 2004.
20. Michaelson MD, Kaufman DS, Lee H. : Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonistinduced bone loss in men with prostate cancer. J Clin Oncol., 25, 1038-42, 2007.